BMJ Open

Relationship between serum insulin-like growth factor 1 levels and ischaemic stroke: a systematic review and meta-analysis

Yangni Li,1 Weinan Yang,1 Jinhui Li,2 Yishu Zhang,1 Lincheng Zhang,1 Simiao Chen 1,1 Lan He,1 Yuyan Zhang1

To cite: Li Y, Yang W, Li J, et al. Relationship between serum insulin-like growth factor 1 levels and ischaemic stroke: a systematic review and meta-analysis. BMJ Open 2022;12:e045776. doi:10.1136/bmjopen-2020-045776

ABSTRACT

Objective To assess the association of insulin-like growth factor 1 (IGF-1) with the risk of incident ischaemic stroke and outcome after ischaemic stroke.

Design A systematic review of primary studies.

Setting Hospitals in Western Sweden, Italy, China and Denmark.

Methods A search was carried out in eligible studies in electronic databases (PubMed, Scopus, Embase, China National Knowledge Infrastructure and Web of Science) updated to 29 December 2020. The relevant data were extracted in order to conduct the meta-analysis. Review Manager V5.2 was used to pool data and calculate the mean difference (MD) and its 95% CI. Heterogeneity, subgroup analysis, sensitivity analysis and publication bias were also performed in this meta-analysis.

Results A total of 2277 patients were included in 17 studies. This meta-analysis indicated that higher serum IGF-1 levels were significantly correlated with less risk of ischaemic stroke (MD=−45.32, 95% CI −63.70 to −26.94), p<0.00001, I2=99%) and better improvement of outcome after ischaemic stroke (MD=27.52, 95% CI 3.89 to 51.14, p=0.02, I2=96%). According to subgroup analysis, heterogeneity comes from country, sample size, male and the time from symptom onset to blood collection. Sensitivity analysis showed that there was no significant influence of any individual study on the pooled MD. The effect of high heterogeneity on result credibility was eliminated when four included studies were merged (MD=−30.32, 95% CI −36.52 to −24.11, p<0.00001, I2=0%). Moreover, no potential publication bias was discovered in this meta-analysis.

Conclusion Higher serum IGF-1 was significantly correlated with a lower risk of ischaemic stroke. In view of the high degree of heterogeneity, it may need more studies to confirm the prognostic value of serum IGF-1 levels in ischaemic stroke and explore the sources of heterogeneity.

INTRODUCTION

Insulin-like growth factors (IGFs), confirmed as peptide hormones, share similar structural homology with insulin. IGF-1 protects cells from apoptosis and functions as a vital regulator in cell survival.12 A growing body of evidence has established that IGF-1 influenced vascular function in many different ways, possessing anti-inflammatory properties and inducing vasodilation by promoting nitric oxide production.3 4 Recently, substantial evidence has accrued to demonstrate that IGF-1 plays a significant role in many cerebral diseases, for example, depression in ischemic stroke, cerebrovascular disease and Alzheimer’s disease.5–7

Stroke is a leading cause of death and disability worldwide, especially in the current ageing society.8 Animal studies and observational studies on humans have been trying to establish an association between IGF-1 and the risk of ischaemic stroke. However, the association of IGF-1 with the risk of incident ischaemic stroke still remains unclear. Seven previous studies are exploring the association manifested inconsistent conclusions. On the one hand, five studies showed that IGF-1 possessed a protective effect against ischaemic stroke.8–13 On the other hand, no association between incident ischaemic stroke and IGF-1 was uncovered in two studies.14 15 Moreover, IGF-1 is widely disseminated and highly expressed in the nervous system.16
which exerts neuroprotective effects and accelerates proliferation of neurons. According to some studies, circulating serum IGF-1 is correlated with improvement of functional outcome after ischaemic stroke and might predict outcome after ischaemic stroke. Actually, the outcome after ischaemic stroke relies on complex interactions of multiple factors, and it still needs more studies to disclose whether the association is causative.

This meta-analysis was conducted in order to evaluate the association of IGF-1 with the risk of incident ischaemic stroke and the outcome after ischaemic stroke.

METHODS

Patient and public involvement

This article did not involve patients and or public.

Study protocol

This meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (online additional file 1).

Literature search strategy

PubMed, Scopus, Embase, China National Knowledge Infrastructure (CNKI) and Web of Science were searched for studies published or presented on or before December 29, 2020. Publications are not restricted to English. To achieve maximum sensitivity in the search strategy and to include more extensive studies, Medical Subject Headings (MeSH) terms and the keywords that were retrieved in the field of Title/Abstract were used in combination. “IGF-1” was selected in the MeSH term and “Insulin-Like Somatomedin Peptide I”, “Insulin Like Somatomedin Peptide I”, “Somatomedin C”, “IGF-I-SmC”, “IGF-I” and “Insulin Like Growth Factor I” were retrieved in the field of Title/Abstract. All the above are connected by “OR”. “Stroke” was selected in the MeSH term. Ultimately, “AND” was utilised to connect the two parts. All relevant articles were found first, and then irrelevant articles were manually excluded through title and abstract screening and full-text assessment. To avoid selection bias, all work was carried out independently by two authors.

Eligibility criteria

Studies were included if they fulfilled the following criteria:

- Studies were confined to those involving human subjects.
- There were no restrictions on the information of language, year of the study, patient age, imaging criteria, body mass index (BMI) and the National Institutes of Health Stroke Scale score.
- Study populations had no fewer than 25 cases and no more than 1000 cases.
- Study had a definite inclusion criterion for acute ischaemic stroke.
- Patients who suffered from stroke were confirmed by CT or MRI before treatment.
- Studies reported the complete outcomes.
- Study used a prospective or retrospective cohort design, or nested case–control design.
- If duplicate studies with an accumulating number of patients or something else were published, only the most complete studies were included in the analysis performed in this study.

Data extraction and quality assessment

All data were extracted independently from the tables and figures of included studies by two authors in an unblinded fashion or adjudicated by the third author in case of disagreement. Moreover, another author took responsibility for the accuracy and reliability of all of the extracted data. The modified Rankin Scale (mRS) is a clinical poststroke functional independence assessment tool. For each study, the study characteristics (author, publication year, study period, country), main characteristics of the patients (age gender and BMI) and outcomes (the number of ischaemic stroke patients, the number of people in control, serum IGF-1 and mRS at 90 days) were extracted independently by two authors. The quality of the included studies was assessed by two other authors using the modified Newcastle-Ottawa Scale, while 6 points or more was considered to be of high quality.

Outcome measure

The Mean, SD, total of serum IGF-1 (ng/mL) in case and control groups is a main indicator of stroke risk assessment. The mRS is an evaluation tool to assess the clinical poststroke functional independence (detailed grades of mRS: 0—no symptoms; 1—no significant disability; 2—slight disability; 3—moderate disability; 4—moderately severe disability; 5—severe disability; 6—dead). The prespecified primary outcome measures were the mRS score of 0–2 and the mRS score 3–6.

Statistical analyses

Statistical analysis was implemented using Review Manager V.5.2 (The Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen, Denmark). The combined effect of mean difference (MD) and 95% CI was defined by a random-effect model or a fixed-effect model or a fixed-effect model in this study.
Table 1: Basic characteristics of included studies in the meta-analysis

| Study           | Study period | Country         | The time from symptom onset to blood collection | Age (year)* † | Male (%) | BMI (kg/m²)* † | Follow-up duration | IGF-1 (ng/mL) | Risk (mean, SD or IQR, Total) | mRS (mean, SD, Total) |
|-----------------|--------------|-----------------|-----------------------------------------------|---------------|----------|----------------|-------------------|--------------|-------------------------------|----------------------|
| Fu et al (2001) | Not stated   | China           | NA                                            | 57–74         | 55.00    | NA             | NA                | 205.7, 125.8, 20 | 472.6, 317.9, 20             | NA                   |
| Sun et al (2001)| 1998.9–1999.10| China           | ≤24 hours                                     | 67            | 70.00    | 26.45±2.51    | NA                | 91, 51, 30     | 175, 49, 30                  | NA                   |
| Liu et al (2002)| 1999.2–2002.3| China           | 3 days                                        | 63.85±8.74    | 63.33    | 27±5          | NA                | 94, 27, 60     | 185, 30, 30                  | NA                   |
| Denti et al (2004)| 1998.1–2000.6| Italy           | ≤24 hours                                     | 83±7          | 34.12    | 25±5          | 6 months          | 69, 45, 85     | 102, 67, 88                  | NA                   |
| Zhang et al (2004)| 2000.12–2001.6| China           | NA                                            | 64±11         | 66.67    | NA             | NA                | 99.48, 33.76, 57 | 179.9, 35.47, 26             | NA                   |
| Johnsen et al (2005)| 1993.12–1997.5| Denmark       | NA                                            | 50–64         | 61.00    | 26.5±4.0      | NA                | 107.1, 33.3, 254 | 112.9, 33.2, 254             | NA                   |
| Geng et al (2006)| 2003.6–2004.1| China           | ≤48 hours                                     | 65.08±10.93   | 70.27    | NA             | NA                | 153.22, 64.56, 56 | 196.1, 33.43, 10             | NA                   |
| Peng et al (2009)| 2006.12–2008.6| China           | ≤48 hours                                     | NA            | NA       | NA             | NA                | 10.4, 1.6, 22  | 28.2, 7.8, 30                | NA                   |
| Chen et al (2010)| 2009.1–2009.12| China          | ≤24 hours                                     | 65.64±7.59    | 55       | NA             | NA                | 73.5, 28, 40   | 103.3, 5.8, 20               | NA                   |
| Åberg et al (2011)| 1998.8–2003.12| Western Sweden | 4 days                                        | 55.5±0.86     | 56.65    | 26.2±0.43     | 3 months          | 172, 3, 388    | 145, 9, 40                   | NA                   |
| Dong et al (2014)| 2011.8–2013.8| China           | ≤24 hours                                     | 66 (57–77)    | 58.75    | 23.9 (22.6–26.8) | NA                | 129, 44, 221  | 140, 34, 200                | NA                   |
| Tang et al (2014)| 2012.8–2013.8| China           | ≤24 hours                                     | 72 (62–83)    | 53.57    | 25.3 (21.8–28.4) | 3 months          | 127, 50, 168  | 155, 38, 100                | 114, 29, 113, 146, 43, 55 |
| Zhang et al (2016)| 2013.2–2015.9| China           | NA                                            | 65.2±8.6      | 56.00    | 26.28±1.59   | 3 months          | 87.92, 25.31, 50 | 152.21, 29.32, 50             | NA                   |
| Li et al (2016) | 2014.5–2015.6| China           | 3 days                                        | 51.9±9.6      | 56.41    | 23.9±6.1     | NA                | 98.66, 20.91, 39 | 153.01, 26.35, 43             | NA                   |
| Armbrust et al (2017)| NA           | Western Sweden | ≤24 hours                                    | 72.9±9.5      | 55.1     | 26.8±4.4     | 3 months          | NA            | NA                           | 131.7, 55.7, 315, 114.2, 55.3, 89 |
| Tao and Wang (2018)| 2016.1–2017.3| China           | 3 days                                        | 60.30±9.75    | 66.67    | NA            | 3 months          | 106.54, 48.84, 60 | 199.2, 53.15, 30             | 145.81, 49.89, 57, 85.56, 32.16, 48 |
| Åberg et al (2019)| 1998–2003    | Western Sweden  | ≤24 hours                                     | 55.3±11       | 65.12    | NA            | 7 years           | NA            | NA                           | 151.5, 6.6, 256, 148.3, 12.3, 67 |

*Median (IQR). †Mean (SD). BMI, body mass index; IGF-1, insulin-like growth factor 1; mRS, modified Rankin Scale; NA, not available.
| Study             | Exposed cohort | Non-exposed cohort | Ascertainment of exposure | Outcome of interest | Control for factor | Assessment of outcome | Follow-up long enough | Adequacy of follow-up | Total score |
|-------------------|----------------|--------------------|---------------------------|--------------------|-------------------|----------------------|-----------------------|-----------------------|-------------|
| Fu et al (2001)   | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Sun et al (2001)  | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Liu et al (2002)  | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Denti et al (2004)| *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 8           |
| Zhang et al (2004)| *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Johnsen et al (2005)| *       | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Geng et al (2006) | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 7           |
| Peng et al (2009) | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Chen et al (2010) | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 7           |
| Åberg et al (2011)| *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 8           |
| Dong et al (2014) | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Tang et al (2014) | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 8           |
| Zhang et al (2016)| *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 8           |
| Li et al (2016)   | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 6           |
| Armbrust et al (2017)| *       | *                  | *                         | *                  | †                 | *                    | *                     |           | 8           |
| Tao et al (2018)  | *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 8           |
| Åberg et al (2019)| *              | *                  | *                         | *                  | †                 | *                    | *                     |           | 9           |

*The study scored one point in the project; †The study scored two points in the project.
model. The heterogeneity among included studies was
tested using the inconsistency index ($I^2$). A random-effect
model was used when there was a high level of heteroge-
neity ($I^2$ values>50%). A $p<0.05$ was considered statisti-
cally significant. For indicators with higher heterogeneity,
sensitivity analysis and subgroup analyses were carried out
to identify the reliability of the meta-analysis and meta-
regression was used to explore the sources of heteroge-
eity. Publication bias was evaluated qualitatively by visual
observation of funnel graphs and was assessed quantita-
tively by the Begg’s test (Stata V.12.0), which manifests a
publication bias with $p<0.05$. The number, MD, SD of the
experimental group and control group of the included
studies were imported into Stata V.12.0 software.

RESULTS

Study selection and characteristics

Detailed steps of the inclusion and exclusion criteria of
the study are shown in figure 1. Briefly, a total of 705
studies were retrieved through 5 electronic database
searches. Thirty-eight additional studies were identified
from the references of included studies after removing
the duplicates. On the basis of extraneous titles and
abstracts, 526 studies were excluded. Several studies were
excluded because they were reviews, non-human experi-
ments; did not present the corresponding outcomes and
lack usable data. Ultimately, the final meta-analysis was
conducted after a complete evaluation of 17 studies that
met the inclusion criteria.10–14 20–23 The basic characteris-
tics and quality score of the included studies are presented
in table 1. The quality score of studies was proven to be
acceptable (table 2).

Relationship between serum IGF-1 and ischaemic stroke risk

The relationship between serum IGF-1 and ischaemic
stroke patients was evaluated, and there was a high
degree of heterogeneity among these included fifteen
studies ($I^2$=99%). Thus, the random-effects model was
used to pool MDs. The consequence manifested a signif-
icant difference (MD$=-45.32$, 95% CI$=-63.70$ to$=-26.94$,
$p<0.00001$, $I^2$=99%, random effect) (figure 2).

Regression of heterogeneity sources

There is high heterogeneity in analyses so we use meta-
regression to explore heterogeneity. From the analysis
results, we can see that the sample size may be the primary
source of heterogeneity (table 3).

Subgroup analysis of heterogeneity sources

In view of enormous heterogeneity, subgroup analysis of
heterogeneity sources was performed to explore heteroge-
eity sources. The heterogeneity of each subgroup
decreased modestly to varying degrees. Notably, the
heterogeneity of the time from symptom onset to blood
collection presented a significant decrease in parallel
with other subgroup results (table 4).

Sensitivity analysis and adjusted relationship between serum
IGF-1 and ischaemic stroke

Sensitivity analysis was performed by omitting one study
by turn, which showed that there was no significant
influence of any individual study on the pooled MDs
(figure 4). Moreover, in pursuit of a low degree of hetero-
geunity and to uncover low degree of heterogeneity
sources, the included studies were randomly merged. It
was discovered that heterogeneity reached its minimum
when four included studies were merged (MD$=-30.92$,
95% CI$=-36.52$ to $-24.11$), $p<0.00001$, $I^2$=0%) (figure 5A).10 13 21 23 The other eleven included studies,
in the other hand, remained high degree of heteroge-
eity (MD$=-50.34$, 95% CI$=-72.82$ to$=-27.87$, p<0.00001,
I²=99%) (figure 5B).\textsuperscript{11,12,14,22,24–30} Taken together, high degree of heterogeneity seemed not to discredit the final merged result.

Publication bias analysis
According to Begg’s test (p=0.092>0.05) and the funnel plot (figure 6), no potential publication bias among the 17 included studies was noted in this meta-analysis.

DISCUSSION

The mechanism of serum IGF-1 in evaluating the risk and prognosis of ischaemic stroke

This meta-analysis merged 17 studies comprising 2277 patients to evaluate the association of serum IGF-1 with the risk of incident ischaemic stroke and the prognostic value of serum IGF-1 in ischaemic stroke. The results demonstrated that serum IGF-1 could be used to evaluate the risk of incident ischaemic stroke (MD = −45.32, 95% CI −63.70 to −26.94, p<0.00001, I²=99%, random effect) and the outcome after ischaemic stroke (MD = 27.52, 95% CI 3.89 to 51.14, p=0.02, I²=99%, random effect). The main mechanism is as follows: Serum IGF-1 mainly comes from the liver, a small part comes from the kidneys and peripherals.\textsuperscript{31} In body fluids, IGF-1 has a high affinity with IGF binding proteins (IGFBPs). IGFBPs regulate the biological activity and bioavailability of IGF-1, and the intake of serum IGF-1 enters the cerebrospinal fluid through the blood–brain barrier.\textsuperscript{32} IGF-1 binds to the widely distributed receptor IGF-1 receptor (IGF-1R) in the brain to activate the two main signal pathways of PI3K/Akt and MAPK, thereby inhibiting neuronal apoptosis,\textsuperscript{33} promoting the survival of oligodendrocytes\textsuperscript{34} and protecting the hippocampus.\textsuperscript{35}

Discussion on the causes of heterogeneity

However, there was an inevitable high degree of heterogeneity among the included studies in this meta-analysis. In order to make the conclusion more persuasive and scientific, subgroup analysis was performed to explore the heterogeneity sources. As the results suggested, the time from symptom onset to blood collection appeared to be part of the source of heterogeneity, while heterogeneity decreased modestly to varying degrees. A study reported that stroke severity was related to decreased IGF-1 in rats as well as humans, which meant that the different stroke severity of recruited patients may also cause heterogeneity.\textsuperscript{11,36} Besides, insufficient follow-up duration may be the heterogeneity source. Due to the inability to obtain the original data, the heterogeneity from the time of symptom onset to blood collection, follow-up duration and stroke severity of recruited patients cannot be explored further. By scrutinising the included studies, it was found that ischaemic stroke patients who were recruited were subjected to the WHO criteria in some included studies,\textsuperscript{10,12,13} whereas others included studies were not subjected to the criteria. In addition to different patient recruitment criteria, the nutritional status of the

Table 4 Subgroup analysis of heterogeneity sources

| Item                        | Subgroup     | No of studies | MD       | 95% CI       | P value | Heterogeneity (I²) |
|-----------------------------|--------------|---------------|----------|--------------|---------|--------------------|
| Country                     | Asian        | 12            | −55.44   | (−72.07 to 38.82) | <0.00001 | 97%                |
|                             | Non-Asian    | 3             | −2.92    | (−32.42 to 26.58) | 0.85    | 99%                |
| Sample size                 | ≥100         | 6             | −18.84   | (−45.77 to 8.08) | 0.17    | 99%                |
|                             | <100         | 9             | −65.16   | (−88.48 to 41.83) | <0.00001 | 97%                |
| Male                        | ≥60%         | 6             | −65.89   | (−107.51 to 24.26) | 0.02    | 98%                |
|                             | <60%         | 8             | −35.21   | (−65.91 to 4.52)  | 0.2     | 99%                |
| The time from symptom onset to blood collection | ≤48 hours | 7             | −30.04   | (−40.05 to 20.03) | <0.00001 | 86%                |
|                             | >48 hours    | 4             | −52.40   | (−120.79 to 15.99) | 0.13    | 99%                |
|                             | ≤24 hours    | 5             | −33.76   | (−49.51 to 18.01) | <0.0001 | 89%                |

MD, mean difference.
patient may cause heterogeneity, which can be indirectly reflected by BMI. Many ischaemic stroke patients are followed by accelerated catabolism and decreased food intake, which results in a decrease in body muscle mass and BMI. The current study cannot rule out the possible effect of malnutrition on serum IGF-1. Moreover, forest plots in the sensitivity analysis (figure 4) and of the adjusted relationship between serum IGF-1 and ischaemic stroke risk (figure 5) both demonstrate that the exclusion of any included study and a high degree of heterogeneity do not affect the final combined result.

The relationship between growth hormone and IGF-1 in cerebrovascular diseases
Growth hormone (GH) exerts much of its biological activity by promoting the production of IGF-1, and IGF-1 can also mediate the effects of GH in turn. The majority of circulating serum IGF-1 is completed with IGFBPs and acid labile subunits, which prevent IGF-1 from binding to the insulin receptor or modulate IGF-1’s binding to the IGF-1R.\textsuperscript{37} It is universally acknowledged that the bioavailability of IGF-1 is regulated by IGFBPs and that only unbound or free IGF-1 possesses biological activity. As part of the body’s ageing process, IGF-1 decreases sharply. Some human studies demonstrate that the effects of circulating serum IGF-1 on cerebrovascular events may be induced by metabolic syndrome.\textsuperscript{28,30} Furthermore, patients with GH deficiency may have lower circulating IGF-1 levels, which raises the risk of cerebrovascular diseases significantly.\textsuperscript{10} Notably, it was reversible with GH replacement.\textsuperscript{41}

Insufficiency of previous related research
Previous studies assessing the association of IGF-1 with the risk of incident ischaemic stroke and the prognostic value of serum IGF-1 in ischaemic stroke reported controversial findings. A study performed by Dong et al.\textsuperscript{11} suggested that lower IGF-1 levels are significantly related to risk of stroke and stroke severity, but IGFBPs levels were not obtained in that biologically active IGF-1 was not fully represented.\textsuperscript{11} Johnsen et al.\textsuperscript{40} found inverse associations between levels of IGF-1 and IGFBP-3 and the risk of ischaemic stroke. However, another study showed no association with incident ischaemic stroke.\textsuperscript{15} Meanwhile, Åberg et al.\textsuperscript{43} suggested that serum IGF-1 levels were closely related to improvements in the mRS and Scandinavian Stroke Scale tested at 3 and 24 months. However, the widespread variation of sampling may have influenced conclusions. Mattlage et al.\textsuperscript{42} reported the potential importance of the change in IGF-1 and IGF-1 ratio to IGFBP-3 during the first week of stroke in understanding recovery. The limitation of the study was that serum IGF-1 levels were not supplemented with the levels of IGF-1 in the cerebral spinal fluid (CSF). Because in ischaemic stroke, IGF-1 transfers from the blood to the CSF. Nevertheless, another study showed an inconsistent conclusion that higher serum IGF-1 levels were modestly associated with better outcomes after ischaemic stroke.\textsuperscript{20}

Strengths and limitations
To our knowledge, this meta-analysis is the first one to investigate the relationship between serum IGF-1 levels and ischaemic stroke. Shaheen et al.\textsuperscript{43} have found that serum IGF-1 was an independent risk factor for ischaemic stroke in the Egyptian population which is consistent with our study. This research has geographical limitations so this meta-analysis included both English and Chinese studies so that publication bias was avoided to a great extent. Besides, the eligibility criteria that study populations were not less than 25 cases and not more than 1000 cases to prevent large samples from affecting the overall results. Åberg et al.\textsuperscript{43} have proved that levels of serum IGF-1 are associated with near 3-month outcomes. However, the study only included 354 patients, meaning that the sample size is too small. Otherwise, a comprehensive database search was performed in this meta-analysis, and as a result, 17 studies comprising a total of 2277 patients were included. Despite the shining points of this meta-analysis, its limitations and shortcomings should be emphasised. A high degree of heterogeneity may cause the unreliability of the results. Meanwhile, Beggs test of publication bias was not performed on the relationship between serum IGF-1 and post-stroke functional independence due to insufficient included studies. Ultimately, a data-feasible study\textsuperscript{15} was excluded because of oversize cases, ambiguous patient recruitment criteria and no mention of stroke confirmed by imaging examination.

The clinical significance and future prospects of the study
Because the majority of serum IGF-1 binds to IGFBPs, the current measured serum IGF level cannot accurately represent the biological activity of IGF in circulation. It is hoped that the future meta-analysis will use the data obtained by the IGF-1-specific tyrosine kinase receptor activation analysis method\textsuperscript{32} as much as possible. This method indirectly measures the actual biological activity by accurately assessing the activity of the official receptor. This meta-analysis significantly analysed that higher IGF-1 correlated with a lower risk of ischaemic stroke. It provides a basis for in-depth clinical research on the relationship...
between the level of IGF-1 and the neurological score \(^{30}\) of stroke patients, poststroke depression \(^{45}\) and dementia \(^{46}\) and so on. In addition, it is also of great significance to the prevention of stroke (identification of high-risk groups and chemoprevention), early diagnosis, clinical treatment and prognosis.

CONCLUSIONS

This meta-analysis analysed all the available interrelated information in the published studies and found that higher serum IGF-1 was significantly correlated with a lower risk of ischaemic stroke. Concerning the relationship between serum IGF-1 and outcome after ischaemic stroke, it may need more studies to confirm the prognostic value of serum IGF-1 levels.

Contributors

YL and WY are co-first authors. YL and WY designed the study. WY, YIZ and HL performed the literature search. WY, YL and LZ selected the studies for inclusion in the meta-analysis. SC and YL extracted the data. WY performed the statistical analysis. YL, WY and JL wrote the manuscript. LH and YuZ revised the manuscript. YUz provided the funding and is a guarantor. All authors read and approved the final manuscript.

Funding

This work was jointly supported by grants from Zhejiang Provincial Natural Science Foundation of China (No.LY21H720012) and the National Natural Science Foundation of China (No.81473587,81774230).

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

All data relevant to the study are included in the article or uploaded as online supplemental information. All data analysed during this study are included in this article.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Yangni Li http://orcid.org/0000-0002-1020-2453
Simiao Chen http://orcid.org/0000-0001-8766-2012

REFERENCES

1. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003;13:113–70.
2. Mehta S, Livingstone C, Borai A, et al. Insulin-Like growth factor binding protein-1 in insulin resistance and cardiovascular disease. Br J Diabetes Vasc Dis 2012;12:17–25.
3. Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999;22:82–8.
4. Gillespie CM, Merkel AL, Martin AA. Effects of insulin-like growth factor-I and Lr3Gf-I on regional blood flow in normal rats. J Endocrinol 1997;155:351–8.
5. Higashi Y, Gautam S, Delafontaine P, et al. IGF-1 and cardiovascular disease. Growth Horm IGF Research 2019;45:5–16.
6. Zhang W, Wang W, Kuang L. The relation between insulin-like growth factor 1 levels and risk of depression in ischemic stroke. Int J Geriatr Psychiatry 2019;33:228–33.
7. Duron E, Funalot B, Brunel N, et al. Insulin-Like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer’s disease. J Clin Endocrinol Metab 2012;97:4673–81.
8. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet Neurol 2016;15:913–24.
9. Saber H, Himaji JJ, Beiser AS, et al. Serum insulin-like growth factor 1 and the risk of ischemic stroke: the Framingham study. Stroke 2017;48:1760–5.
10. Denti L, Annoni V, Cattadori E, et al. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004;117:312–7.
11. Dong X, Chang G, Ji X-F, et al. The relationship between serum insulin-like growth factor 1 levels and ischemic stroke risk. PLoS One 2014;9:e84845.
12. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-Like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005;90:5937–41.
13. Tang J-H, Ma L-L, Yu T-X, et al. Insulin-like growth factor-1 as a prognostic marker in patients with acute ischemic stroke. PLoS One 2014;9:e99186.
14. Åberg D, Jood K, Blomstrand C, et al. Serum IGF-1 levels correlate to improvement of functional outcome after ischemic stroke. J Clin Endocrinol Metab 2011;96:e1055–66.
15. Kaplan RC, McCann AP, Pollak MN, et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 2007;92:1319–25.
16. Reinhardt RR, Bondy CA. Insulin-Like growth factors cross the blood-brain barrier. Endocrinology 1994;135:1753–61.
17. De Smedt A, Brouns R, Uyttenboogaart M, et al. Insulin-Like growth factor I serum levels influence ischemic stroke outcome. Stroke 2011;42:2180–5.
18. Zatelli MC, LaveZZi S, Bergonzoni A, et al. Data from: predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2016;91:3928–34.
19. Armbrust M, Worthmann H, Dengler R, et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 predict Three-months outcome after ischemic stroke. Exp Clin Endocrinol Diabetes 2017;125:455–61.
20. Åberg ND, Åberg D, Lagging C, et al. Association between levels of serum insulin-like growth factor I and functional recovery, mortality, and recurrent stroke at a 7-year follow-up. Exp Clin Endocrinol Diabetes 2020;128:303–310.
21. Chen L, AL L. Data from: clinical significance and level of IGF-1 in blood of patients with cerebral infarction. Jilin University 2010.
22. XF F, YL L, LU K. Changes of serum insulin-like growth factor-1 and insulin-like growth factor-3 in acute stroke patients. Chin J Crit Care Med 2001;21.
23. Geng JL, Zhang Y, Miao L. Data from: effect of serum insulin-like growth factor-1 levels on the prognosis of acute ischemic stroke patients. Chin J Contemp Neuroly 2006;6.
24. KY L, Guo Q, Zhang J. Data from: changes and clinical significance of serum insulin-like growth factor-1 and ferritin levels in patients with type-2 diabetes and cerebral infarction. Chin J Diabetes 2016;24.
25. Liu N, Zheng A, Chen YL. Data from: changes of serum insulin-like growth factor-1 and insulin-like growth factor-3 in acute stroke patients. Chin J Arterioscler 2002;10.
26. Peng GJ, Song HB, Zhang SY. Data from: the level and clinical significance of insulin-like growth factor-1 in acute progressive cerebral infarction. Medical Research and Education 2009;26.
27. Sun YH, Guan W, Yuan RY. Data from: changes and clinical significance of serum insulin-like growth factor-1 in cerebral infarction patients. Chin J Geriatr Cardiovasc Cerebrovasc Dis 2013.
28. Tao HY, Wang XP. Data from: study on changes of serum insulin-like growth factor-1 level and related factors in acute ischemic stroke patients. World Clinical Drugs 2018;39.
29. Zhang H, Guo Y, Zheng DM. Data from: association between serum insulin-like growth factor-1 level and neurological deficit score in acute cerebral infarction patients. Chinese J Rehabilitation Med 2004;8.
30. Zhang BQ, Dong QC, Zhang YX. Data from: association between level of serum insulin-like growth factor-I in type-2 diabetes patients companied with acute cerebral infarction and neurological deficit score. *Neural Injury And Functional Reconstruction* 2016;11.

31. Sjögren K, Liu J-L, Blad K, et al. Liver-Derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. *Proc Natl Acad Sci U S A* 1999;96:7088–92.

32. Numao A, Suzuki K, Miyamoto M, et al. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. *Parkinsonism Relat Disord* 2014;20:212–6.

33. Selvamani A, Sohrabji F, Arnnutha S, Farida S. The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. *J Neurosci* 2010;30:6852–61.

34. Gong X, Ma M, Fan X, et al. Down-Regulation of IGF-1/IGF-1R in hippocampus of rats with vascular dementia. *Neurosci Lett* 2012;513:20–4.

35. Selvamani A, Sathyan P, Miranda RC, et al. An antagonist to microRNA Let7f promotes neuroprotection in an ischemic stroke model. *PLoS One* 2012;7:e32662.

36. Selvamani A, Sathyan P, Miranda RC, et al. An antagonist to microRNA Let7f promotes neuroprotection in an ischemic stroke model. *PLoS One* 2012;7:e32662.

37. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2008;28:812–9.

38. Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. *Lancet* 2002;359:1740–5.

39. Perticone F, Sciaccia A, Tassone EJ, et al. One-Hour post-load plasma glucose and IGF-1 in hypertensive patients. *Eur J Clin Invest* 2012;42:1325–31.

40. Bülöv B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. *Clin Endocrinol* 1997;46:75–81.

41. Pfeifer M, Verhoeve R, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. *J Clin Endocrinol Metab* 1999;84:453–7.

42. Mattiagl AE, Rippet MA, Sandt J, et al. Decrease in insulin-like growth factor-1 and insulin-like growth factor-1 ratio in the first week of stroke is related to positive outcomes. *J Stroke Cerebrovasc Dis* 2016;25:1800–6.

43. Shaheen H, Sobhy S, El Mously S, et al. Insulin-Like growth factor-1 in acute ischemic stroke. *Egypt J Neurol Psychiatr Neurosurg* 2018;54:42.

44. Åberg ND, Åberg D, Jood K, et al. Altered levels of circulating insulin-like growth factor-I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study. *BMC Neurol* 2018;18:106.

45. Wang YZ. Data from: clinical study on the effect of Peiyuan Jieyu acupuncture method on insulin-like growth factor-1 level in patients with post-stroke depression. *Fujian University of Traditional Chinese Medicine* 2019.

46. Huang YY, Xu J, MH Y. Data from: study on the relationship between serum insulin-like growth factor-1 level and dementia after stroke. *Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Diseases* 2007;05:304–7.